[Skip to Content]
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
Purchase Options:
[Skip to Content Landing]

September 2018 - July 1883

Decade

Year

Issue

July 17, 2018, Vol 320, No. 3, Pages 1-316

In This Issue of JAMA

Highlights

Abstract Full Text
free access has audio
JAMA. 2018;320(3):215-217. doi:10.1001/jama.2017.12460
Viewpoint

How HIPAA Harms Care, and How to Stop It

Abstract Full Text
JAMA. 2018;320(3):229-230. doi:10.1001/jama.2018.8829

In this Viewpoint, Berwick and Gaines review common misconceptions about Health Insurance Portability and Accountability Act (HIPAA) requirements regarding personal health information and propose steps the Department of Health and Human Services (DHHS) can take to better balance privacy protections with the need to ensure health information is available for clinical care in reasonable time at reasonable expense.

HIPAA and Protecting Health Information in the 21st Century

Abstract Full Text
free access
JAMA. 2018;320(3):231-232. doi:10.1001/jama.2018.5630

This Viewpoint posits that HIPAA no longer fully protects health information in today’s big data era in which health data are collected and exchanged in nonclinical settings, such as social media, apps, and search engines, and proposes principles around which reform of health information privacy protections should be organized.

Health Data and Privacy in the Digital Era

Abstract Full Text
JAMA. 2018;320(3):233-234. doi:10.1001/jama.2018.8374

This Viewpoint discusses personal health information on social media and other sites and ways in which this information can and should be protected.

A Piece of My Mind

And Still We Believed

Abstract Full Text
JAMA. 2018;320(3):235. doi:10.1001/jama.2018.8654

This narrative medicine essay explores the difference between understanding a dire prognosis and believing it.

Editorial

Digital Media and Symptoms of Attention-Deficit/Hyperactivity Disorder in Adolescents

Abstract Full Text
JAMA. 2018;320(3):1-2. doi:10.1001/jama.2018.8932

Bridging the Evidence-to-Practice Gap in Stroke Care

Abstract Full Text
JAMA. 2018;320(3):236-237. doi:10.1001/jama.2018.8803

The Status of End-of-Life Care in the United StatesThe Glass Is Half Full

Abstract Full Text
JAMA. 2018;320(3):239-241. doi:10.1001/jama.2018.10062

USPSTF Recommendations for Assessment of Cardiovascular Risk With Nontraditional Risk FactorsFinding the Right Tests for the Right Patients

Abstract Full Text
JAMA. 2018;320(3):242-244. doi:10.1001/jama.2018.9346
Original Investigation

Effect of a Multifaceted Quality Improvement Intervention on Hospital Personnel Adherence to Performance Measures in Patients With Acute Ischemic Stroke in ChinaA Randomized Clinical Trial

Abstract Full Text
has active quiz
JAMA. 2018;320(3):245-254. doi:10.1001/jama.2018.8802

This cluster randomized clinical trial determines whether a multifaceted quality improvement intervention can improve adherence to evidence-based performance measures in patients with acute ischemic stroke in China.

Association of Digital Media Use With Subsequent Symptoms of Attention-Deficit/Hyperactivity Disorder Among Adolescents

Abstract Full Text
has active quiz
JAMA. 2018;320(3):255-263. doi:10.1001/jama.2018.8931

This 24-month cohort study tracks high school students in Los Angeles County, California, who were not initially assessed as having ADHD symptoms to compare frequency of use of digital media platforms with experiencing ADHD symptoms.

Caring for the Critically Ill Patient

Site of Death, Place of Care, and Health Care Transitions Among US Medicare Beneficiaries, 2000-2015

Abstract Full Text
JAMA. 2018;320(3):264-271. doi:10.1001/jama.2018.8981

This population epidemiology study characterizes trends in care in the intensive care unit during the last 30 days of life and in posthospital transitions and site of death among Medicare beneficiaries who died between 2000 and 2015.

US Preventive Services Task Force

Recommendation Statement

Risk Assessment for Cardiovascular Disease With Nontraditional Risk FactorsUS Preventive Services Task Force Recommendation Statement

Abstract Full Text
free access has active quiz
JAMA. 2018;320(3):272-280. doi:10.1001/jama.2018.8359

This 2018 Recommendation Statement from the US Preventive Services Task Force concludes that current evidence is insufficient to assess the balance of benefits and harms of adding ABI, hsCRP, or CAC score measures to traditional risk assessment for CVD in asymptomatic adults to prevent CVD events (I statement).

Evidence Report

Nontraditional Risk Factors in Cardiovascular Disease Risk AssessmentUpdated Evidence Report and Systematic Review for the US Preventive Services Task Force

Abstract Full Text
free access
JAMA. 2018;320(3):281-297. doi:10.1001/jama.2018.4242

This systematic review to support the 2018 US Preventive Services Task Force Recommendation Statement on use of nontraditional risk factors in cardiovascular disease risk assessment summarizes published evidence on the benefits and harms of using ABI, hsCRP, and CAC score measures in CVD risk assessment and decisions about initiation of preventive therapy.

JAMA Diagnostic Test Interpretation

Carcinoembryonic Antigen for Diagnosis of Colorectal Cancer Recurrence

Abstract Full Text
JAMA. 2018;320(3):298-299. doi:10.1001/jama.2018.8424

A 78-year-old man with a carcinoembryonic antigen (CEA) level of 11.0 ng/mL but no evidence of metastasis underwent a right hemicolectomy (surgical pathology showed a 5.5-cm adenocardinoma with 0 of 19 lymph nodes positive for cancer). At 6 months, CEA was 3.0 ng/mL. At 12 months, CEA was 5.1 ng/mL and then 6.1 ng/mL with repeat testing. What would you do next?

Research Letter

Clinical Trial Evidence Supporting FDA Approval of Drugs Granted Breakthrough Therapy Designation

Abstract Full Text
JAMA. 2018;320(3):301-303. doi:10.1001/jama.2018.7619

This study used the Drugs@FDA database to review FDA-approved “breakthrough” therapies from 2012 to 2017 (characterizing the pivotal clinical trials that serve as the basis of FDA approval), and premarket development and review times to assess the strength of evidence supporting breakthrough approvals.

Medical News & Perspectives

“Is There a Doctor on the Plane?”

Abstract Full Text
has audio
JAMA. 2018;320(3):221-223. doi:10.1001/jama.2018.6654

In this Medical News article, frequent traveler Rachel Zang, MD, talks about her experiences helping ill patients aboard commercial airline flights and discusses what all physicians should know about in-flight medical emergencies.

What’s the Best Way to Treat Normal-Weight People With Metabolic Abnormalities?

Abstract Full Text
JAMA. 2018;320(3):223-225. doi:10.1001/jama.2018.8188

This Medical News story discusses different approaches to treating normal-weight individuals who have metabolic abnormalities that are usually associated with overweight and obesity.

News From the Food and Drug Administration

Generic for Opioid Use Disorder

Abstract Full Text
JAMA. 2018;320(3):1. doi:10.1001/jama.2018.9584

FDA Prods “Clean Meat” Discussion

Abstract Full Text
JAMA. 2018;320(3):228. doi:10.1001/jama.2018.9507

Caffeine Supplement Warning

Abstract Full Text
JAMA. 2018;320(3):228. doi:10.1001/jama.2018.9508
The JAMA Forum

The Risks and Benefits of Expedited Drug Reviews

Abstract Full Text
free access
JAMA. 2018;320(3):225-226. doi:10.1001/jama.2018.8262
Global Health

Efforts to Address Snakebite

Abstract Full Text
JAMA. 2018;320(3):227. doi:10.1001/jama.2018.9118

Global Temperature Affects Dengue

Abstract Full Text
JAMA. 2018;320(3):227. doi:10.1001/jama.2018.9737

Older People With Disabilities Overlooked in Humanitarian Response

Abstract Full Text
JAMA. 2018;320(3):227. doi:10.1001/jama.2018.9738
Comment & Response

Prophylactic Haloperidol for Critically Ill Adults

Abstract Full Text
JAMA. 2018;320(3):303. doi:10.1001/jama.2018.6041

Prophylactic Haloperidol for Critically Ill Adults

Abstract Full Text
JAMA. 2018;320(3):303-304. doi:10.1001/jama.2018.6045

Prophylactic Haloperidol for Critically Ill Adults—Reply

Abstract Full Text
JAMA. 2018;320(3):304-305. doi:10.1001/jama.2018.6049

Diagnosis and Treatment of Acute Respiratory Distress Syndrome

Abstract Full Text
JAMA. 2018;320(3):305. doi:10.1001/jama.2018.5924

Diagnosis and Treatment of Acute Respiratory Distress Syndrome

Abstract Full Text
JAMA. 2018;320(3):305-306. doi:10.1001/jama.2018.5928

Diagnosis and Treatment in Acute Respiratory Distress Syndrome—Reply

Abstract Full Text
JAMA. 2018;320(3):306. doi:10.1001/jama.2018.5932

Off-label Use of Medications

Abstract Full Text
JAMA. 2018;320(3):306-307. doi:10.1001/jama.2018.6517

Off-label Use of Medications—Reply

Abstract Full Text
JAMA. 2018;320(3):307-308. doi:10.1001/jama.2018.6521
Correction

Data Errors in Figure 3 and Labels Transposed in Figure 4

Abstract Full Text
free access
JAMA. 2018;320(3):308. doi:10.1001/jama.2018.9635

Removal of Drug Name From the Table

Abstract Full Text
free access
JAMA. 2018;320(3):308. doi:10.1001/jama.2018.9636
Poetry and Medicine

Shadow Children

Abstract Full Text
JAMA. 2018;320(3):309. doi:10.1001/jama.2018.1460
JAMA Revisited

Relation of Education to Preventive Medicine

Abstract Full Text
JAMA. 2018;320(3):310. doi:10.1001/jama.2017.12468
JAMA Patient Page

Risk Assessment for Cardiovascular Disease With Nontraditional Risk Factors

Abstract Full Text
free access
JAMA. 2018;320(3):316. doi:10.1001/jama.2018.9122

This JAMA Patient Page describes the US Preventive Services Task Force recommendations on assessment for cardiovascular disease using nontraditional risk factors.

JAMA Masthead

JAMA

Abstract Full Text
free access
JAMA. 2018;320(3):219-220. doi:10.1001/jama.2017.12461
×